Business
Medical Marijuana, Inc. Subsidiary HempMeds® Brasil Announces New Chief Medical Officer
Medical Marijuana, Inc. Subsidiary HempMeds® Brasil Announces New Chief Medical Officer.
About this update from Medical Marijuana, Inc.
[{"type":"text","content":"\n\n\n\nMedical Marijuana, Inc. Subsidiary HempMeds® Brasil Announces New Chief Medical Officer\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nMedical Marijuana, Inc. Subsidiary HempMeds® Brasil Announces New Chief Medical Officer\nPR Newswire\nSAN DIEGO, Feb. 4, 2020\n\n\n\nSAN DIEGO, Feb. 4, 2020 /PRNewswire/ -- Medical Marijuana, Inc. (OTC: MJNA) (the \"Company\"), the first-ever publicly traded cannabis company in the United States that launched the world's first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that its subsidiary HempMeds® Brasil has appointed Dr. Rubens Wajnsztejn as the Company's Chief Medical Officer.\n\"More than just someone who believes in the power of cannabidiol (CBD), Dr. Wajnsztejn is an expert researcher and has direct contact with many Brazilian doctors and future health professionals who need to be educated on this compound's potential wellness benefits,\" said HempMeds® Brasil Vice President Caroline Heinz. \"He will be joining our team to help us further establish relationships with hospitals and medical practices throughout Brazil and oversee studies to test the safety and efficacy of our products.\"\nDr. Wajnsztejn is a neuropediatric doctor and the former president of the Brazilian Society of Child Neurology. He boasts over three decades of education with a master's degree in Human Communication Disorders from Unifesp (Federal University of the State of São Paulo) and holds a Ph.D. in Health Sciences at the Center Universitário Saúde (ABC), where he teaches and specializes in autism and CBD prescription.\n\"According to analysts at New Frontier Data, Brazil's cannabis market could be worth around $4.4 billion by 2022, totaling more than six percent of the overall revenue of the Brazilian pharmaceutical industry,\" said Medical Marijuana, Inc. CEO Dr. Stuart Titus. \"We strongly believe that Dr. Wajnsztejn can help us reach more decision-makers and doctors in Brazil to expand our sales and brand awareness.\"\nOne of Dr. Wajnsztejn's ma...